Drug intelligence / Profile preview

nimbolide

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Nimbolide is a bioactive, highly oxidized, tetranortriterpenoid limonoid compound derived primarily from the leaves and flowers of the neem tree (*Azadirachta indica*)[1][2][4][6]. It possesses **anti-inflammatory**, **antioxidant**, **anticancer**, **antimicrobial**, and **antimalarial** effects in experimental settings[1][3][5]. Nimbolide acts by **modulating multiple molecular and signaling pathways**, such as Mitogen-activated protein kinases (MAPKs), Wnt-β/catenin, NF-κB, PI3K/AKT, TGF-β, STAT3, Notch-1, PTEN/PI3K/AKT, ERK 1/2, LXRα, and PPARγ. It inhibits pro-inflammatory cytokines (TNF-α, IL-1α, IL-1β, IL-6), nitrosative-oxidative stress, and downstream effectors such as matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), and epithelial-mesenchymal transition (EMT) proteins. Mechanistically, it demonstrates potent cytotoxicity in cancer models through induction of apoptosis, inhibition of metastasis and angiogenesis, anti-proliferative effects, modulation of carcinogen-metabolizing enzymes, and epigenetic modulation (e.g., histone deacetylase inhibition)[1][3][4]. Nimbolide is currently in preclinical development and has not advanced to clinical trials[3].

Other names
nimbolide
02

Targets

NR1H3 (Liver X receptor beta)PPARG (Peroxisome proliferator-activated receptor gamma)MMP12 (Macrophage Metalloelastase)MEKNOTCH (Neurogenic locus notch homolog protein 3)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on nimbolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nimbolide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call